非小细胞肺癌免疫治疗的现状与未来

Current Status and Future Prospect of Immunotherapy for Non-small Cell Lung Cancer

免疫治疗在非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗中已经取得重大进展,主要包括从晚期NSCLC的二线治疗走向一线治疗,并扩展到局部晚期NSCLC的巩固治疗、早中期NSCLC的新辅助治疗和辅助治疗;从全人群覆盖过渡到精准人群选择;从单药治疗扩展到联合治疗等。然而,在此领域仍然存在诸多尚未解决的问题,包括免疫治疗的机制有待深入研究、寻找合适的疗效预测生物标志物、探索最佳免疫联合治疗模式和关注特殊人群的免疫治疗选择等。随着基础研究和临床试验的全面推进,NSCLC免疫治疗疗效将会得到更大改善。

The immunotherapy for non-small cell lung cancer(NSCLC)has achieved tremendous progress in recent years.It has become the first-line treatment from the second-line,and expanded to consolidation therapy for locally advanced NSCLC,neoadjuvant therapy and adjuvant therapy for early and mid-stage NSCLC.It has be applied from covering all patients to more precisely selected patients,from monotherapy to combination therapy.However,there are still unresolved problems in this field,including investigating the mechanism of immunotherapy,finding proper predictive biomarkers,exploring the best combination regimen,and paying attention to selecting special group of patients.With the comprehensive development of basic research and clinical trials,the immunotherapy will be a more effective therapeutic modality for NSCLC patients in the future.